HEALTHEQUITY, INC.
Nasdaq: HQY·Draper, Utah·CIK 0001428336
- Price
- $104.58
- Base IV
- $76.11
Valuation snapshot
At $104.58, the price sits between our base case ($76.11) and bull case ($120.38).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $76.11
- 73% of the price · range $44.09–$120.38
- Price vs base case
- 37% above
- $104.58 against $76.11
- Base case · our researched forecast, 2026-10-31See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has risen 3.2% since this valuation was struck on 2026-10-31, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $44.09 to bull $120.38. Values per share.
Price against each value
- Bear case
- $44.09
- Price 137% above
- No growth
- …
- —
- Base case
- $76.11
- Price 37% above
What does Healthequity do?
HealthEquity provides technology-enabled administration and investment services for employers and employees to manage health savings accounts (HSAs) and other consumer-directed benefits like FSAs and HRAs.
It brought in $1.4B of sales in the 12 months to Jul 2026.
- Based in
- Draper, Utah
- Trades on
- Nasdaq as HQY
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Jul 2026, about 17¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 29¢ of every dollar.
- Making what it sells29¢
- Research and development20¢
- Sales, marketing and admin17¢
- Everything else it takes to operate8¢
- Interest and other costs3¢
- Tax5¢
- Left as profit17¢
Who pays Healthequity, and for what?
HealthEquity provides cloud-based technology services to help consumers save, spend, and invest healthcare funds using tax-advantaged accounts like HSAs, FSAs, and HRAs. It earns revenue through administration and investment fees, interest earned on member cash and client deposits, and interchange fees when members swipe payment cards for healthcare expenses.
Employers pay HealthEquity to administer benefits for their employees, while health plans, account holders, and merchants also pay associated service, custodial, or interchange fees.
Custodial revenue
48%Interest and yield earned on member HSA cash placed with insurance company partners and custodial depository banks, as well as on client-held funds.
Service revenue
37%Monthly administration fees charged to employers and partners for managing HSAs and other benefits, plus advisory and investment fees from invested HSA assets and marketplace offerings.
Interchange revenue
15%Transaction fees paid by merchants whenever members use HealthEquity physical debit payment cards or virtual payment platforms to pay for eligible healthcare expenses.
HealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026
How is the business doing?
Sales grew from $733.6M in 2021 to $1.3B in 2026, about 12% a year.
Running the business leaves about 26¢ of each sales dollar as operating profit, up from 5¢ in 2021.
After paying for its upkeep and new investment, it had $487.7M of cash to spare in the 12 months to Jul 2026.
What does management say it's aiming for?
The company exists to empower American healthcare consumers to make better saving, spending, and investing choices to improve their financial and physical health.
“To save and improve lives by empowering healthcare consumers.”
What management says it is working on now:
Transitioning HSA Cash to Enhanced Rates
Management is shifting maturing depository cash contracts into group annuity insurance contracts that deliver higher yields and reduce short-term interest rate sensitivity.
HealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026Modernizing Cloud and AI Infrastructure
Investing in proprietary platform modernization and AI tools, such as HSAnswers and Expedited Claims, to drive automation, reduce servicing costs, and expand self-service.
HealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026Expanding Bundled HSA and CDB Distribution
Leveraging integrations with over 200 health plans and retirement recordkeepers to cross-sell bundled HSA, FSA, HRA, and commuter benefits to enterprise employers.
HealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026Managing Interest Rate Risk Through Forward Hedging
Deploying Treasury bond forwards to pre-hedge benchmark interest rates on future HSA cash placements and stabilize custodial earnings against rate declines.
HealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026Integrating Acquired HSA Portfolios
Maintaining an active selective acquisition strategy to acquire and onboard third-party HSA accounts and assets, such as the BenefitWallet portfolio.
HealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026
- Revenue, Fiscal year ending January 31, 2027
- $1.411 billion to $1.421 billion
- HealthEquity Reports Second Quarter Fiscal 2027 Financial Results
- Adjusted EBITDA, Fiscal year ending January 31, 2027
- $628 million to $636 million
- HealthEquity Reports Second Quarter Fiscal 2027 Financial Results
- Non-GAAP Net Income, Fiscal year ending January 31, 2027
- $392 million to $398 million
- HealthEquity Reports Second Quarter Fiscal 2027 Financial Results
- GAAP Net Income, Fiscal year ending January 31, 2027
- $242 million to $248 million
- HealthEquity Reports Second Quarter Fiscal 2027 Financial Results
What's changing right now?
Growth is holding steady. In Q2 2027 it sold 8% more than a year earlier. The year before, quarters averaged 8%.
Its operating margin is about where it was a year ago, 28¢ per sales dollar.
Since Oct 2026 the share price has risen 3%, from $101.36 to $104.58.
Coming up
Throughout fiscal year ending January 31, 2027
HSA Cash Repricing and Portfolio Reinvestment
$4.5 billion of custodial HSA cash earning an average 1.9% yield is scheduled to reprice during fiscal 2027, creating potential yield expansion into higher contract rates.
HealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026Q3 and Q4 Fiscal 2027 (October 2026 - January 2027)
Annual Fall Employer Benefits Open Enrollment
The annual autumn benefits enrollment window determines corporate client adoption, new HSA account additions, and total account growth entering the new calendar year.
HealthEquity Reports Second Quarter Fiscal 2027 Financial ResultsOngoing through 2026 and 2027
Implementation of Expanded Plan Eligibility Rules
Regulatory changes under the One Big Beautiful Bill Act expanding HSA availability to Bronze and Catastrophic plans provide a broader addressable market for account additions.
HealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Interest Rate Fluctuations and Yield Compression
A broader decline in prevailing interest rates would lower the custodial yields earned on HSA cash and client-held funds, which generate nearly half of total company revenues.
From the company's own filingsWould hit how fast sales growHealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026
Cybersecurity Breaches and Data Privacy Incidents
The company is a frequent target for cyber attacks; past partner data breaches have triggered regulatory inquiries, legal claims, and significant investigation and remediation expenses.
From the company's own filingsWould hit how much of each sale it keepsHealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026
Outside Fraud and Credential Attacks on Accounts
Sophisticated outside fraud targeting member accounts has caused substantial direct reimbursement and service costs, and further fraud could erode client trust and brand reputation.
From the company's own filingsWould hit how much of each sale it keepsHealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026
Changes to Tax Law and Health Benefit Regulations
Substantially all revenue relies on tax-favored account status. Any legislative reduction or repeal of tax deductions for HSAs or CDBs would severely damage account adoption.
From the company's own filingsWould hit its growth in the long runHealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026
Custodial Partner Risk and Lack of Insurance Coverage
HSA cash held with insurance company partners under Enhanced Rates is not federally insured, exposing members and the business to counterparty financial instability or default.
From the company's own filingsWould hit how fast sales growHealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026
Intensifying Competition from Large Financial Institutions
Major competitors like Fidelity and Optum possess greater financial resources and brand reach, putting downward pressure on administrative fees and risking partner attrition.
From the company's own filingsWould hit how fast sales growHealthEquity, Inc. Form 10-K for the Fiscal Year Ended January 31, 2026
Annual revenue growth slowed from 20.0% in FY2025 to 9.5% in FY2026 and 7.6% in Q2 FY2027, indicating natural post-acquisition normalization.
From our researchWould hit how fast sales growHealthEquity FY 2026 Form 10-K
Is it a good business?
From 2019 to 2026 it earned between -1% and 56% on the capital invested in it, a median of 4%. Its cost of capital in the latest valuation is 6.8%; returns were above it in 2 of the 8 years.
From 2017 to 2026 it earned between -2% and 15% on its shareholders' equity, a median of 4%.
Over 10 years its operating margin ranged from 3¢ to 27¢ per sales dollar, a median of 14¢. Gross margin ran from 56¢ to 70¢.
Cost of capital 6.8%
It bought back shares: the count fell 4.3% in a year, so each remaining share owns a slightly bigger slice.
It owes $675.1M more than it holds in cash, about 1.9 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $104.58. Our put its value between $44.09 and $120.38, with $76.11 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $44.09
This scenario envisions a marked cooling in customer additions alongside declining interest rates on savings balances, dampening revenue expansion and squeezing profitability back toward historical lows.
Base case, $76.11
This scenario assumes the company delivers on its raised full-year targets while maintaining steady single-digit revenue expansion and strong profitability as recent system integrations bear fruit.
Bull case, $120.38
This scenario envisions robust double-digit expansion in customer savings balances and rising payment transactions, driving significant profit gains as modern technology lowers the cost of serving each account.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 37%
For Healthequity to be worth today's $104.58, sales would need to grow about 13.3% a year. We assume 6.5%. Over the last 5 years, sales grew 13.0% a year.
Or, if sales grow 6.5% as we assume, the price works with a profit margin of 36.8% (we assume 27.5%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 13.3% a year?
Try your own numbersWe're moderately sure of this range: it scores 58 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $76.11 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average6.5%
- Operating margin27.5%
- Long-term growth rate2.8%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$76.11 -27.2%

